Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma
暂无分享,去创建一个
[1] A. Sihoe,et al. The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.
[2] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[3] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[4] S. Digumarthy,et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S. Ou,et al. Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] E. Campo,et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. , 2009, The American journal of pathology.
[7] A. Iafrate,et al. Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.
[8] Y. Ishikawa,et al. Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts , 2008, Clinical Cancer Research.
[9] Yuki Togashi,et al. EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] Y. Ishikawa,et al. KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.
[11] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[12] J. Minna,et al. Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features , 2006, Clinical Cancer Research.
[13] A. Iafrate,et al. A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry , 2010, Clinical Cancer Research.
[14] Huqun,et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. , 2005, Cancer research.
[15] Y. Ishikawa,et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset , 2009, Modern Pathology.
[16] W. Pao,et al. EML4-ALK: honing in on a new target in non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Laura A. Sullivan,et al. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.